Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Kalunian

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Arthritis and Rheumatism|November 13, 2002
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosusBetty P Tsao, Rita M Cantor, Jennifer M Grossman, et al.
Arthritis and Rheumatism|October 18, 2002
Familiality and co-occurrence of clinical features of systemic lupus erythematosusBetty P Tsao, Jennifer M Grossman, Gabriela Riemekasten, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 7, 2016
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled TrialsMegan E B Clowse, Daniel J Wallace, Richard A Furie, et al.
Arthritis and Rheumatism|August 31, 2012
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusKenneth C Kalunian, W Winn Chatham, Elena M Massarotti, et al.
Lancet (London, England)|July 26, 2018
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialDaniel J Wallace, Richard A Furie, Yoshiya Tanaka, et al.
Lupus Science & Medicine|May 7, 2020
Cell-bound complement activation products associate with lupus severity in SLECristina Arriens, Roberta Vezza Alexander, Sonali Narain, et al.
Annals of Internal Medicine|June 22, 2005
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trialJill P Buyon, Michelle A Petri, Mimi Y Kim, et al.
The New England Journal of Medicine|December 16, 2005
Combined oral contraceptives in women with systemic lupus erythematosusMichelle Petri, Mimi Y Kim, Kenneth C Kalunian, et al.
Arthritis Care & Research|January 24, 2023
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate ModelingAnn E Clarke, John G Hanly, Murray B Urowitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception CohortJohn G Hanly, Caroline Gordon, Sang-Cheol Bae, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Arthritis and Rheumatism|November 13, 2002
Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosusBetty P Tsao, Rita M Cantor, Jennifer M Grossman, et al.
Arthritis and Rheumatism|October 18, 2002
Familiality and co-occurrence of clinical features of systemic lupus erythematosusBetty P Tsao, Jennifer M Grossman, Gabriela Riemekasten, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 7, 2016
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled TrialsMegan E B Clowse, Daniel J Wallace, Richard A Furie, et al.
Arthritis and Rheumatism|August 31, 2012
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusKenneth C Kalunian, W Winn Chatham, Elena M Massarotti, et al.
Lancet (London, England)|July 26, 2018
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialDaniel J Wallace, Richard A Furie, Yoshiya Tanaka, et al.
Lupus Science & Medicine|May 7, 2020
Cell-bound complement activation products associate with lupus severity in SLECristina Arriens, Roberta Vezza Alexander, Sonali Narain, et al.
Annals of Internal Medicine|June 22, 2005
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trialJill P Buyon, Michelle A Petri, Mimi Y Kim, et al.
The New England Journal of Medicine|December 16, 2005
Combined oral contraceptives in women with systemic lupus erythematosusMichelle Petri, Mimi Y Kim, Kenneth C Kalunian, et al.
Arthritis Care & Research|January 24, 2023
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate ModelingAnn E Clarke, John G Hanly, Murray B Urowitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2021
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception CohortJohn G Hanly, Caroline Gordon, Sang-Cheol Bae, et al.
Pageof 9